<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="EN"><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title>PLoS ONE</journal-title><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">08-PONE-RA-04944R1</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0004187</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline"><subject>Cardiovascular Disorders/Vascular Biology</subject><subject>Non-Clinical Medicine/Academic Medicine</subject><subject>Pathology/Cellular Pathology</subject></subj-group></article-categories><title-group><article-title>Host-Derived Smooth Muscle Cells Accumulate in Cardiac Allografts: Role of Inflammation and Monocyte Chemoattractant Protein 1</article-title><alt-title alt-title-type="running-head">Vascular Progenitor</alt-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Religa</surname><given-names>Piotr</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="cor1"><sup>&#x0002a;</sup></xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Grudzinska</surname><given-names>Monika K.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Bojakowski</surname><given-names>Krzysztof</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Soin</surname><given-names>Joanna</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Nozynski</surname><given-names>Jerzy</given-names></name><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Zakliczynski</surname><given-names>Michal</given-names></name><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Gaciong</surname><given-names>Zbigniew</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Zembala</surname><given-names>Marian</given-names></name><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>S&#x000f6;derberg-Naucl&#x000e9;r</surname><given-names>Cecilia</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>Cellular and Molecular Immunology, Karolinska Institute, Stockholm, Sweden</addr-line></aff><aff id="aff2"><label>2</label><addr-line>Department of Internal Medicine and Hypertension, Warsaw University of Medicine, Warsaw, Poland</addr-line></aff><aff id="aff3"><label>3</label><addr-line>Department of General, Vascular and Oncologic Surgery, Warsaw University of Medicine, Warsaw, Poland</addr-line></aff><aff id="aff4"><label>4</label><addr-line>Department of General Biochemistry and Nutrition, Warsaw University of Medicine, Warsaw, Poland</addr-line></aff><aff id="aff5"><label>5</label><addr-line>Silesian Center for Heart Diseases, Zabrze, Poland</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Westermark</surname><given-names>Per</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">Uppsala University, Sweden</aff><author-notes><corresp id="cor1">&#x0002a; E-mail: <email>piotr.religa@ki.se</email></corresp><fn fn-type="con"><p>Conceived and designed the experiments: PR MKG KB JS JN MZ ZG MZ CSN. Performed the experiments: PR MKG KB JS. Analyzed the data: PR MKG KB JS JN MZ ZG MZ CSN. Contributed reagents/materials/analysis tools: PR MKG KB JS JN MZ ZG MZ CSN. Wrote the paper: PR MKG KB JS ZG CSN.</p></fn></author-notes><pub-date pub-type="collection"><year>2009</year></pub-date><pub-date pub-type="epub"><day>14</day><month>1</month><year>2009</year></pub-date><volume>4</volume><issue>1</issue><elocation-id>e4187</elocation-id><history><date date-type="received"><day>3</day><month>6</month><year>2008</year></date><date date-type="accepted"><day>5</day><month>12</month><year>2008</year></date></history><copyright-statement>Religa et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</copyright-statement><copyright-year>2009</copyright-year><abstract><p>Transplant arteriosclerosis is characterized by inflammation and intimal thickening caused by accumulation of smooth muscle cells (SMCs) both from donor and recipient. We assessed the relationship between clinical factors and the presence of host-derived SMCs in 124 myocardial biopsies from 26 consecutive patients who received hearts from opposite-sex donors. Clinical and demographic information was obtained from the patients' medical records. Host-derived SMCs accounted for 3.35&#x000b1;2.3&#x00025; of cells in arterioles (range, 0.08&#x02013;12.51&#x00025;). As shown by linear regression analysis, an increased number of SMCs was associated with rejection grade (mean, 1.41&#x000b1;1.03, p&#x0200a;&#x0003d;&#x0200a;0.034) and the number of leukocytes (19.1&#x000b1;12.7 per 20 high-power fields, p&#x0200a;&#x0003d;&#x0200a;0.01). The accumulation of host-derived SMCs was associated with an increased number of leukocytes in the allografts. In vitro, monocyte chemoattractant protein 1 (MCP-1) released from leukocytes was crucial for SMC migration. After heart allotransplantion, mice treated with MCP-1-specific antibodies had significantly fewer host-derived SMCs in the grafts than mice treated with isotypic antibody controls. We conclude that the number of host-derived SMCs in human cardiac allografts is associated with the rejection grade and that MCP-1 may play pivotal role in recruiting host-derived SMCs into cardiac allografts.</p></abstract><counts><page-count count="8"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>The major cause of late organ dysfunction after transplantation is vasculopathy characterized by vessel inflammation and intimal hyperplasia due to the recruitment of smooth muscle cells (SMCs) into the vessel intima <xref ref-type="bibr" rid="pone.0004187-Libby1">&#x0005b;1&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004187-Lietz1">&#x0005b;2&#x0005d;</xref>. This process results in progressive luminal narrowing caused in part by a healing reaction in the intima. The intimal cells could be derived from phenotypically modulated medial SMCs within the graft or from host-derived SMCs <xref ref-type="bibr" rid="pone.0004187-Bojakowski1">&#x0005b;3&#x0005d;</xref>. Possible sources of the host-derived cells in cardiac allografts are cells in adjacent vessels that migrate toward the graft, circulating tissue progenitors, or possibly bone marrow&#x02013;derived progenitors <xref ref-type="bibr" rid="pone.0004187-Hillebrands1">&#x0005b;4&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0004187-Sata1">&#x0005b;6&#x0005d;</xref>. Although host-derived cells contribute to transplant vasculopathy, their clinical significance and the mechanisms of their accumulation in the intima are unknown.</p><p>Transplant vasculopathy is believed to have both immunological and nonimmunological causes and results in vascular dysfunction due to factors affecting the allograft <xref ref-type="bibr" rid="pone.0004187-Libby1">&#x0005b;1&#x0005d;</xref>. Diverse immunological factors that contribute to chronic transplant dysfunction have been identified, including the degree of acute rejection, immunosuppression, and opportunistic infections, particularly cytomegalovirus infection <xref ref-type="bibr" rid="pone.0004187-Orloff1">&#x0005b;7&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004187-SoderbergNaucler1">&#x0005b;8&#x0005d;</xref>. Nonimmunological factors, such as the age of the recipient, underlying diseases, and ischemia, also contribute to chronic transplant dysfunction.</p><p>In this study, we investigated clinical factors that influence the accumulation of host-derived cells in arterioles of human cardiac allografts and potential factors involved in their migration. We analyzed archived myocardial biopsies from heart transplant recipients mismatched in sex with their donors, which enabled us to determine the origin of SMCs in the vessel lesions. We also performed in vitro migration assays and in vivo heart transplantation studies in mice.</p></sec><sec sec-type="materials|methods" id="s2"><title>Materials and Methods</title><sec id="s2a"><title>Biopsies of human cardiac allografts</title><p>We analyzed 124 post-transplantation cardiac biopsy specimens from 26 consecutive patients who received cardiac allografts from opposite-sex donors from 1994&#x02013;2003. Specimens were from the tissue bank at the Silesian Center for Heart Disease (Zabrze, Poland). The protocol was approved by the regional board of the ethics committee at the Karolinska Institute and conformed to the principles outlined in the Declaration of Helsinki. All patients gave informed consent. Specimens were obtained by endomyocardial biopsy as part of a standard procedure for monitoring acute graft rejection (weekly for the first month, every 2 weeks for the second month, every 3 months until end of the first year, every 6 months during the second year, and yearly thereafter). Biopsies not containing arterioles were excluded from analysis.</p><p>Specimens were analyzed by pathologist using the criteria of the International Society for Heart and Lung Transplantation <xref ref-type="bibr" rid="pone.0004187-Stewart1">&#x0005b;9&#x0005d;</xref>. Rejection was graded according to the following scale: 0, no rejection; 1A, focal (perivascular or interstitial) infiltrate without necrosis; 1B, diffuse but sparse infiltrate without necrosis; 2, a single focus of aggressive infiltration and/or focal myocyte damage; 3A, multifocal aggressive infiltrates and/or myocyte damage; 3B diffuse inflammation and necrosis; and 4 diffuse aggressive polymorphous infiltrate, edema, hemorrhage, vasculitis, and necrosis. Samples were also analyzed by immunohistochemistry for the accumulation of host-derived SMCs in arterioles.</p></sec><sec id="s2b"><title>Clinical information</title><p>Retrospective clinical and demographic data were collected from the patients' medical records. The clinical data included age, time from transplantation, underlying diseases (hypertension, diabetes, smoking, gastric ulcer, hepatopathy, episodes of thromboembolism, heart, lung and kidney failure, cancer, hypercholesterolemia), and blood morphology. Information about immunosuppression and infection with cytomegalovirus, hepatitis B virus, hepatitis C virus, and human immunodeficiency virus was obtained at the time of hospitalization for myocardial biopsy. To assess heart function, echocardiography was performed to estimate the ejection fraction.</p></sec><sec id="s2c"><title>Immunohistochemistry</title><p>Immunohistochemistry was performed as described <xref ref-type="bibr" rid="pone.0004187-Religa1">&#x0005b;10&#x0005d;</xref> with primary antibodies against human smooth muscle &#x003b1;-actin (&#x003b1;SMA), vonWillebrand factor (vWF), CD45, CD14, CD3, CD8, CD 4, IgG and IgM (Dako, Glostrup, Denmark), MCP-1 (Biolegend, San Diego, CA). Vessels positive for &#x003b1;SMA and vWF and cells positive for CD45, CD14, CD3, CD8, and CD4 were manually counted in 20 high-power fields (HPF) and averaged. IgG and IgM levels were scored as low, medium, or high.</p></sec><sec id="s2d"><title>Laser capture microdissection of &#x003b1;SMA-positive arterioles</title><p>Laser capture microdissection was performed on tissue sections stained for &#x003b1;SMA. In three to four sections from each biopsy, 300&#x02013;400 &#x003b1;SMA-positive cells were microdissected from arterioles with the PixCell II System (Arcturus Engineering, Mountain View, CA). The percentage of host-derived cells among captured cells was estimated by real-time PCR for the <italic>SRY</italic> gene as described <xref ref-type="bibr" rid="pone.0004187-Religa1">&#x0005b;10&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004187-Lo1">&#x0005b;11&#x0005d;</xref>.</p></sec><sec id="s2e"><title>In situ hybridization for chromosome Y</title><p>Tissue sections were rehydrated in xylene-graded ethanol, boiled in citrate buffer for 15 min to unmask epitopes, and incubated with anti-&#x003b1;SMA antibodies overnight at 4&#x000b0;C. After fixation in 4&#x00025; formalin in phosphate-buffered saline for 15 min, the sections were placed in 2&#x000d7; saline sodium citrate (SSC)/0.5 NP-40 at 37&#x000b0;C for 30 min and dehydrated in 70&#x00025; and 95&#x00025; ethanol for 2 min each, denatured in 70&#x00025; formamide/2&#x000d7; SSC at 72&#x000b0; for 20 min, and dehydrated in ice-cold ethanol. The sections were then hybridized with 10 &#x000b5;l of probe for 16 h in a humidified chamber and washed with 0.5&#x000d7; SSC for 5 min at 72&#x000b0;C, 50&#x00025; formamide/2&#x000d7; SSC at 43&#x000b0;C for 15 min, and 0.1&#x000d7; SSC at 60&#x000b0;C for 15 min. Finally, the sections were counterstained with propidium iodide, mounted in Mountex (Vector), and examined by confocal microscopy (Leica TCS SP5).</p></sec><sec id="s2f"><title>Cell migration assay</title><p>The migration of SMCs was measured with a modified Boyden chamber (NeuroProbe). Cells (60,000/well) were seeded into the upper chamber in serum-free Ham's F-12 medium containing 0.2&#x00025; bovine serum albumin. Ham's F-12 medium containing monocyte chemoattractant protein (MCP) 1 (50 ng) or leukocyte-conditioned medium was added to the lower chamber. In migration inhibition experiments, we added MCP-1 antibodies to the medium in the lower chamber or anti-CCR2 to the cells 30 min before the experiment. After a 6-h incubation, the medium was removed, and cells attached to the bottom of the filter were fixed in 99&#x00025; methanol, stained with a Giemsa solution, and examined by light microscopy. The mean number of cells per microscopic field (magnification, 20&#x000d7;) was plotted. All experiments were repeated three or four times.</p></sec><sec id="s2g"><title>Mouse heart allograft transplantation</title><p>Balb mice were used as donors of vascularized cardiac allografts. The protocol was approved by the ethics committee at Warsaw Medical University and conformed to the principles in the Declaration of Helsinki. The mice were anesthetized with medetomidine (1 mg/g) and ketamine (75 mg/g), and vascularized cardiac grafts were collected and transplanted into recipient GFP mice as described <xref ref-type="bibr" rid="pone.0004187-Huang1">&#x0005b;12&#x0005d;</xref>. The aorta and pulmonary artery of the donor heart were anastomosed to the recipient abdominal aorta and inferior vena cava, respectively. Allograft survival was evaluated by daily palpation. Cessation of beating was interpreted as rejection. Between days 5&#x02013;10 after transplantation, mice received anti-MCP-1 or isotypic antibodies (10 mg/kg i.v.). The hearts were collected, cut into 5-&#x000b5;m-thick sections, stained immunohistochemically for CD45, CD68, CD3, CD8, CD4, and &#x003b1;SMA, and analyzed by confocal microscopy.</p></sec><sec id="s2h"><title>Data presentation and statistical analysis</title><p>Data analyses and event classifications were performed by investigators blinded to the clinical information. Values are expressed as mean&#x000b1;SD or as means and medians with SD. Associations between accumulation of host-derived SMCs and predictors of cellular accumulation selected from demographical, biochemical/functional, and immunohistochemical data were analyzed by best-subset logistic regression. The Akaike information criterion and manual elimination of risk factors based on medical consideration were used to obtain a parsimonious model with good predictive capability. Leave-one-out cross-validation was used to avoid overfitting of the final model. The final model included only predictors with significant contribution (p&#x0003c;0.05). In all analyses, a two-sided p value&#x0003c;0.05 was considered significant. The results of studies in mice were analyzed with <italic>t</italic> tests; p&#x0003c;0.05 was considered significant.</p></sec></sec><sec id="s3"><title>Results</title><sec id="s3a"><title>Patient characteristics</title><p>Myocardial biopsies were obtained from 26 consecutive patients who received cardiac transplants from donors of the opposite sex. The characteristics of the patients and the indications for transplantation are shown in <xref ref-type="table" rid="pone-0004187-t001">Table 1</xref>. There were 15 women and 11 men (mean age, 41 years). The most common indications for transplantation were ischemic heart disease (n&#x0200a;&#x0003d;&#x0200a;13) and congestive cardiomyopathy (n&#x0200a;&#x0003d;&#x0200a;10). The patients were characterized by hypercholesterolemia (n&#x0200a;&#x0003d;&#x0200a;16), smoking (n&#x0200a;&#x0003d;&#x0200a;9), hypertension (n&#x0200a;&#x0003d;&#x0200a;9), thrombotic episodes (n&#x0200a;&#x0003d;&#x0200a;9), and diabetes (n&#x0200a;&#x0003d;&#x0200a;5). All patients were treated with cyclosporin A, prednisone, and azathioprine/mycophenolate-mofetil.</p><table-wrap id="pone-0004187-t001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0004187.t001</object-id><label>Table 1</label><caption><title>Baseline characteristic of the patients<xref ref-type="table-fn" rid="nt101">&#x0002a;</xref>.</title></caption><graphic id="pone-0004187-t001-1" xlink:href="pone.0004187.t001"/><table frame="hsides" rules="groups" alternate-form-of="pone-0004187-t001-1"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Characteristics</td><td align="left" rowspan="1" colspan="1">Total</td><td align="left" rowspan="1" colspan="1">Females</td><td align="left" rowspan="1" colspan="1">Males</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">No. of patients</td><td align="left" rowspan="1" colspan="1">26</td><td align="left" rowspan="1" colspan="1">15</td><td align="left" rowspan="1" colspan="1">11</td></tr><tr><td align="left" rowspan="1" colspan="1">Number of biopsies (mean&#x0002b;range)</td><td align="left" rowspan="1" colspan="1">124</td><td align="left" rowspan="1" colspan="1">6.6 (4&#x02013;14)</td><td align="left" rowspan="1" colspan="1">2.3 (1&#x02013;4)</td></tr><tr><td align="left" rowspan="1" colspan="1">Mean age (years)</td><td align="left" rowspan="1" colspan="1">41&#x000b1;20.0</td><td align="left" rowspan="1" colspan="1">31.5&#x000b1;21.7</td><td align="left" rowspan="1" colspan="1">53.4&#x000b1;6.8</td></tr><tr><td colspan="4" align="left" rowspan="1">Treatment indication</td></tr><tr><td align="left" rowspan="1" colspan="1">Congestive cardiomyopathy</td><td align="left" rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">5</td></tr><tr><td align="left" rowspan="1" colspan="1">Ischemic heart diseases</td><td align="left" rowspan="1" colspan="1">13</td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">6</td></tr><tr><td align="left" rowspan="1" colspan="1">Hypertrophic cardiomiopaty</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Acquired valve disease</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Cogenital heart disease</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">Diabetes</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">4</td></tr><tr><td align="left" rowspan="1" colspan="1">Smoking</td><td align="left" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">5</td></tr><tr><td align="left" rowspan="1" colspan="1">Re-operation</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">2</td></tr><tr><td align="left" rowspan="1" colspan="1">Hypertension</td><td align="left" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">5</td></tr><tr><td align="left" rowspan="1" colspan="1">Thromboembolic episodes</td><td align="left" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">7</td></tr><tr><td align="left" rowspan="1" colspan="1">Hypercholesterolemia</td><td align="left" rowspan="1" colspan="1">16</td><td align="left" rowspan="1" colspan="1">8</td><td align="left" rowspan="1" colspan="1">8</td></tr><tr><td align="left" rowspan="1" colspan="1">Kidney failure</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">Gastric ulcer</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">0</td></tr><tr><td align="left" rowspan="1" colspan="1">Liver failure</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">2</td></tr></tbody></table><table-wrap-foot><fn id="nt101"><label>&#x0002a;</label><p>Values are numbers of patients, unless indicated otherwise.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3b"><title>Histological findings</title><p>To estimate the number of &#x003b1;SMA-positive host-derived cells in the graft, we used a real-time PCR assay for the <italic>SRY</italic> gene. In each biopsy, host-derived cells accounted for a mean of 3.4&#x000b1;2.3&#x00025; (range, 0.08&#x02013;12.5&#x00025;) of &#x003b1;SMA-positive cells obtained by laser capture microdissection of arterioles. The presence of host-derived SMCs in the allografts was confirmed by in situ hybridization for chromosome Y and immunostaining for &#x003b1;SMA (<xref ref-type="fig" rid="pone-0004187-g001">Fig. 1A</xref>).</p><fig id="pone-0004187-g001" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0004187.g001</object-id><label>Figure 1</label><caption><title>Immunohistochemical characteristic of human cardiac allografts.</title><p>(A) Immunohistochemistry for &#x003b1;SMA (blue) followed by in situ hybridization for chromosome Y (green) and nuclear counterstaining (red). (B&#x02013;K) Immunohistochemical staining of human cardiac allografts for &#x003b1;SMA (B), vWF (C), CD45 (D), CD14 (E), IgG (F), IgM (G), CD4 (H), and CD8 (I). Arrows indicate positive cells and staining. (J and K) Scatter plots showing the association between the number of &#x003b1;SMA-positive cells in the vessel and patient age (J) CD45&#x0002b; cells (K).</p></caption><graphic xlink:href="pone.0004187.g001"/></fig><p>To estimate the extent of rejection, myocardial biopsy samples were graded for lymphocytic infiltration and necrotic changes as described <xref ref-type="bibr" rid="pone.0004187-Stewart1">&#x0005b;9&#x0005d;</xref>. Severe rejection (greater than grade 2) was found in only 29 (23&#x00025;) samples. The numbers of arterioles was determined by staining for &#x003b1;SMA and vWF. During development of vasculopathy, signs of arteriolitis were visible by edema and detachment of endothelial cells, decreased staining for &#x003b1;SMA, luminal narrowing, and changes in morphological structure of vascular wall (<xref ref-type="fig" rid="pone-0004187-g001">Figure 1B, C</xref>). Leukocytes, macrophages, and lymphocytes were identified by staining for CD45, CD14, CD3, CD4, and CD8 (<xref ref-type="fig" rid="pone-0004187-g001">Fig. 1D&#x02013;I</xref>). In all biopsies, the number of infiltrating cells was low but clearly increased with the rejection grade, as expected. CD45<sup>&#x0002b;</sup> leukocytes were the predominant, which accumulated in perivascular regions in samples with grade 2 rejection and increased in number with increasing rejection grade. In grade 3 rejection, these cells also accumulated in areas of cardiomyocytes. In contrast, CD4<sup>&#x0002b;</sup> and CD8<sup>&#x0002b;</sup> lymphocytes were detected in perivascular areas and were rare in cardiomyocyte areas (<xref ref-type="fig" rid="pone-0004187-g001">Fig. 1H, I</xref>). As expected, IgG and IgM accumulated with increasing rejection grade (<xref ref-type="fig" rid="pone-0004187-g001">Fig. 1F, G</xref>).</p></sec><sec id="s3c"><title>Identifying primary predictors of host-derived SMC accumulation in the arterioles</title><p>To identify factors associated with the accumulation of host-derived cells around arterioles in the grafts, we built three separate multiple logistic regression models based on demographic/clinical factors, cellular characteristic, and biochemical/functional variables (<xref ref-type="table" rid="pone-0004187-t002">Table 2</xref>).</p><table-wrap id="pone-0004187-t002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0004187.t002</object-id><label>Table 2</label><caption><title>Logistic linear regression analysis of factors associated with accumulation of vascular progenitor cells in arterioles.</title></caption><graphic id="pone-0004187-t002-2" xlink:href="pone.0004187.t002"/><table frame="hsides" rules="groups" alternate-form-of="pone-0004187-t002-2"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Predicting factors</td><td align="left" rowspan="1" colspan="1">Mean</td><td align="left" rowspan="1" colspan="1">Median</td><td align="left" rowspan="1" colspan="1">SD</td><td align="left" rowspan="1" colspan="1">Lower quartile 25&#x00025;</td><td align="left" rowspan="1" colspan="1">Higher quartile 75&#x00025;</td><td align="left" rowspan="1" colspan="1">p</td></tr></thead><tbody><tr><td colspan="7" align="left" rowspan="1">Demographic</td></tr><tr><td align="left" rowspan="1" colspan="1">Time from biopsy (mo)</td><td align="left" rowspan="1" colspan="1">12.238</td><td align="left" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">12.472</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">18</td><td align="left" rowspan="1" colspan="1">0.054</td></tr><tr><td align="left" rowspan="1" colspan="1">Age (year)</td><td align="left" rowspan="1" colspan="1">35.990</td><td align="left" rowspan="1" colspan="1">40</td><td align="left" rowspan="1" colspan="1">20.008</td><td align="left" rowspan="1" colspan="1">17.25</td><td align="left" rowspan="1" colspan="1">52.75</td><td align="left" rowspan="1" colspan="1">0.010</td></tr><tr><td align="left" rowspan="1" colspan="1">Rejection grade</td><td align="left" rowspan="1" colspan="1">1.414</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">1.031</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">0.010</td></tr><tr><td colspan="7" align="left" rowspan="1">Immunohistochemical</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x003b1;SMA<sup>&#x0002b;</sup> vessels (n)</td><td align="left" rowspan="1" colspan="1">7.200</td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">3.813</td><td align="left" rowspan="1" colspan="1">5</td><td align="left" rowspan="1" colspan="1">9</td><td align="left" rowspan="1" colspan="1">0.013</td></tr><tr><td align="left" rowspan="1" colspan="1">vWF<sup>&#x0002b;</sup> vessels (n)</td><td align="left" rowspan="1" colspan="1">14.206</td><td align="left" rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1">10.280</td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">17</td><td align="left" rowspan="1" colspan="1">0.010</td></tr><tr><td align="left" rowspan="1" colspan="1">CD45<sup>&#x0002b;</sup> cells (n)</td><td align="left" rowspan="1" colspan="1">19.057</td><td align="left" rowspan="1" colspan="1">17</td><td align="left" rowspan="1" colspan="1">12.665</td><td align="left" rowspan="1" colspan="1">11</td><td align="left" rowspan="1" colspan="1">24</td><td align="left" rowspan="1" colspan="1">0.035</td></tr><tr><td align="left" rowspan="1" colspan="1">CD14<sup>&#x0002b;</sup> cells (n)</td><td align="left" rowspan="1" colspan="1">12.500</td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">15.162</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">16</td><td align="left" rowspan="1" colspan="1">0.209</td></tr><tr><td align="left" rowspan="1" colspan="1">CD3<sup>&#x0002b;</sup> cells (n)</td><td align="left" rowspan="1" colspan="1">16.431</td><td align="left" rowspan="1" colspan="1">11</td><td align="left" rowspan="1" colspan="1">13.379</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">25</td><td align="left" rowspan="1" colspan="1">0.048</td></tr><tr><td align="left" rowspan="1" colspan="1">CD8<sup>&#x0002b;</sup> cells (n)</td><td align="left" rowspan="1" colspan="1">5.073</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">4.031</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">0.382</td></tr><tr><td align="left" rowspan="1" colspan="1">CD4<sup>&#x0002b;</sup> cells (n)</td><td align="left" rowspan="1" colspan="1">7.269</td><td align="left" rowspan="1" colspan="1">6</td><td align="left" rowspan="1" colspan="1">4.370</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">10</td><td align="left" rowspan="1" colspan="1">0.897</td></tr><tr><td colspan="7" align="left" rowspan="1">Biochemical/functional</td></tr><tr><td align="left" rowspan="1" colspan="1">Ejection fraction (&#x00025;)</td><td align="left" rowspan="1" colspan="1">57.809</td><td align="left" rowspan="1" colspan="1">57</td><td align="left" rowspan="1" colspan="1">6.470</td><td align="left" rowspan="1" colspan="1">53</td><td align="left" rowspan="1" colspan="1">64</td><td align="left" rowspan="1" colspan="1">0.445</td></tr><tr><td align="left" rowspan="1" colspan="1">Hematocrit (&#x00025;)</td><td align="left" rowspan="1" colspan="1">33.453</td><td align="left" rowspan="1" colspan="1">33</td><td align="left" rowspan="1" colspan="1">3.826</td><td align="left" rowspan="1" colspan="1">31</td><td align="left" rowspan="1" colspan="1">36</td><td align="left" rowspan="1" colspan="1">0.612</td></tr><tr><td align="left" rowspan="1" colspan="1">Hemoglobin (g/dl)</td><td align="left" rowspan="1" colspan="1">7.322</td><td align="left" rowspan="1" colspan="1">7.3</td><td align="left" rowspan="1" colspan="1">1.022</td><td align="left" rowspan="1" colspan="1">6.7</td><td align="left" rowspan="1" colspan="1">7.7</td><td align="left" rowspan="1" colspan="1">0.035</td></tr><tr><td align="left" rowspan="1" colspan="1">White blood cells (&#x000d7;10<sup>6</sup>/l)</td><td align="left" rowspan="1" colspan="1">7.013</td><td align="left" rowspan="1" colspan="1">6.45</td><td align="left" rowspan="1" colspan="1">2.889</td><td align="left" rowspan="1" colspan="1">4.90</td><td align="left" rowspan="1" colspan="1">8.22</td><td align="left" rowspan="1" colspan="1">0.884</td></tr><tr><td align="left" rowspan="1" colspan="1">Cholesterol (mmol/l)</td><td align="left" rowspan="1" colspan="1">5.487</td><td align="left" rowspan="1" colspan="1">5.2</td><td align="left" rowspan="1" colspan="1">1.909</td><td align="left" rowspan="1" colspan="1">4.470</td><td align="left" rowspan="1" colspan="1">6.20</td><td align="left" rowspan="1" colspan="1">0.724</td></tr><tr><td align="left" rowspan="1" colspan="1">Triglycerides (mmol/l)</td><td align="left" rowspan="1" colspan="1">7.027</td><td align="left" rowspan="1" colspan="1">1.7</td><td align="left" rowspan="1" colspan="1">43.462</td><td align="left" rowspan="1" colspan="1">1.180</td><td align="left" rowspan="1" colspan="1">2.40</td><td align="left" rowspan="1" colspan="1">0.766</td></tr><tr><td align="left" rowspan="1" colspan="1">HDL (mmol/l)</td><td align="left" rowspan="1" colspan="1">2.037</td><td align="left" rowspan="1" colspan="1">1.5</td><td align="left" rowspan="1" colspan="1">4.536</td><td align="left" rowspan="1" colspan="1">1.1900</td><td align="left" rowspan="1" colspan="1">1.6350</td><td align="left" rowspan="1" colspan="1">0.645</td></tr><tr><td align="left" rowspan="1" colspan="1">LDL (mmol/l)</td><td align="left" rowspan="1" colspan="1">2.966</td><td align="left" rowspan="1" colspan="1">2.9</td><td align="left" rowspan="1" colspan="1">0.878</td><td align="left" rowspan="1" colspan="1">2.20</td><td align="left" rowspan="1" colspan="1">3.55</td><td align="left" rowspan="1" colspan="1">0.679</td></tr><tr><td align="left" rowspan="1" colspan="1">Cyclosporin A (ng/ml)</td><td align="left" rowspan="1" colspan="1">293.796</td><td align="left" rowspan="1" colspan="1">265.9</td><td align="left" rowspan="1" colspan="1">149.682</td><td align="left" rowspan="1" colspan="1">194.00</td><td align="left" rowspan="1" colspan="1">374.50</td><td align="left" rowspan="1" colspan="1">0.010</td></tr></tbody></table><table-wrap-foot><fn id="nt102"><label/><p>HDL, high density lipoprotein; LDL, low density lipoprotein.</p></fn></table-wrap-foot></table-wrap><sec id="s3c1"><title>Demographic and clinical factors</title><p>This model included time from biopsy, age, gender, rejection grade, and coexisting diseases (<xref ref-type="table" rid="pone-0004187-t001">Table 1</xref>). The presence of host-derived SMCs in the allografts (<xref ref-type="table" rid="pone-0004187-t002">Table 2</xref>, <xref ref-type="fig" rid="pone-0004187-g001">Fig. 1A</xref>) correlated significantly with mean age (40.0&#x000b1;20.0 years, p&#x0200a;&#x0003d;&#x0200a;0.01) (<xref ref-type="fig" rid="pone-0004187-g001">Fig. 1J</xref>) and mean rejection grade (1.4&#x000b1;1.03, p&#x0200a;&#x0003d;&#x0200a;0.01). However, several categorical risk factors, including coexisting diseases and smoking habits, were excluded from the model because of the low number of patients. Biopsy samples were obtained 1&#x02013;70 months (mean, 12.2 months) after transplantation.</p></sec><sec id="s3c2"><title>Cellular characteristics</title><p>In a best-subset logistic regression analysis, the number of arterioles staining positively for &#x003b1;SMA and vWF, the number of CD45<sup>&#x0002b;</sup> leukocytes, and rejection grade independently predicted the accumulation of host-derived SMCs in the allografts. SMCs were significantly less abundant in areas with higher numbers of vWF-positive vessels (mean 14.2&#x000b1;12.3, p&#x0200a;&#x0003d;&#x0200a;0.013) and &#x003b1;SMA (mean 7.2&#x000b1;3.8, p&#x0200a;&#x0003d;&#x0200a;0.01). The number of host-derived cells increased with the number of CD45<sup>&#x0002b;</sup> leukocytes (19.1&#x000b1;12.7, p&#x0200a;&#x0003d;&#x0200a;0.035) (<xref ref-type="fig" rid="pone-0004187-g001">Fig. 1K</xref>). In a step model, those factors were the best predictors of increased accumulation of host SMCs in arterioles (<xref ref-type="table" rid="pone-0004187-t002">Table 2</xref>).</p></sec><sec id="s3c3"><title>Biochemical and functional parameters</title><p>This regression model included blood morphology, lipid data (e.g., plasma levels of total cholesterol, high density lipoproteins, and low density lipoproteins), and plasma concentration of cyclosporin A. Among functional tests of the heart, only the ejection fraction was included; data on other parameters were not collected at the time of biopsy. Hemoglobin and cyclosporin A were associated (p&#x0003c;0.05) with the accumulation of host-derived SMCs in the graft (<xref ref-type="table" rid="pone-0004187-t002">Table 2</xref>).</p></sec></sec><sec id="s3d"><title>Final logistic regression model</title><p>The final model, based on results from the partial models, included the rejection grade, the number of arterioles and CD45<sup>&#x0002b;</sup> leukocytes, hemoglobin levels, and plasma cyclosporin A levels (<xref ref-type="table" rid="pone-0004187-t003">Table 3</xref>). The number of arterioles was significantly related (p&#x0003c;0.05) to the number of accumulated SMCs. The number of host-derived SMCs in arterioles was increased and associated with the rejection grade (mean 1.41&#x000b1;1.03, p&#x0200a;&#x0003d;&#x0200a;0.034) and the number of leukocytes (mean 19.06&#x000b1;12.66 per 20 HPF, p&#x0200a;&#x0003d;&#x0200a;0.01). Cyclosporin A levels correlated inversely with the accumulation of host-derived SMCs (p&#x0200a;&#x0003d;&#x0200a;0.14).</p><table-wrap id="pone-0004187-t003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0004187.t003</object-id><label>Table 3</label><caption><title>Logistic linear regression analysis of the association between predicting factors and accumulation of vascular progenitor cells in arterioles.</title></caption><graphic id="pone-0004187-t003-3" xlink:href="pone.0004187.t003"/><table frame="hsides" rules="groups" alternate-form-of="pone-0004187-t003-3"><colgroup span="1"><col align="left" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/><col align="center" span="1"/></colgroup><thead><tr><td align="left" rowspan="1" colspan="1">Predicting factor</td><td align="left" rowspan="1" colspan="1">Mean</td><td align="left" rowspan="1" colspan="1">Median</td><td align="left" rowspan="1" colspan="1">SD</td><td align="left" rowspan="1" colspan="1">p</td></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Rejection grade</td><td align="left" rowspan="1" colspan="1">1.41</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">1.03</td><td align="left" rowspan="1" colspan="1">0.034</td></tr><tr><td align="left" rowspan="1" colspan="1">&#x003b1;SMA<sup>&#x0002b;</sup> vessels (n)</td><td align="left" rowspan="1" colspan="1">7.20</td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">3.81</td><td align="left" rowspan="1" colspan="1">0.041</td></tr><tr><td align="left" rowspan="1" colspan="1">CD45<sup>&#x0002b;</sup> cells (n)</td><td align="left" rowspan="1" colspan="1">19.06</td><td align="left" rowspan="1" colspan="1">17</td><td align="left" rowspan="1" colspan="1">12.66</td><td align="left" rowspan="1" colspan="1">0.010</td></tr><tr><td align="left" rowspan="1" colspan="1">Hemoglobin (g/dl)</td><td align="left" rowspan="1" colspan="1">7.32</td><td align="left" rowspan="1" colspan="1">7.3</td><td align="left" rowspan="1" colspan="1">1.02</td><td align="left" rowspan="1" colspan="1">0.279</td></tr><tr><td align="left" rowspan="1" colspan="1">Cyclosporin A (ng/ml)</td><td align="left" rowspan="1" colspan="1">293.78</td><td align="left" rowspan="1" colspan="1">265.9</td><td align="left" rowspan="1" colspan="1">149.68</td><td align="left" rowspan="1" colspan="1">0.143</td></tr></tbody></table></table-wrap></sec><sec id="s3e"><title>MCP-1 is a crucial factor for migration of SMCs</title><p>Since the number of leukocytes was associated with increased accumulation of host-derived SMCs in human cardiac allografts, we determined whether leukocytes can influence migration of SMCs. In response to stimulation with leukocyte-conditioned medium, SMC migration increased by approximately 90&#x00025; (<xref ref-type="fig" rid="pone-0004187-g002">Fig. 2</xref>). We recently observed that RNA levels of MCP-1, RANTES, and IP10 are highly increased in aortic allografts. Since MCP-1 is the major factor for monocyte recruitment to inflamed tissues, we hypothesized that it might also be involved in the migration of host-derived SMCs. Indeed, in response to recombinant MCP-1 (50 ng/m), SMC migration increased to levels similar to those induced by leukocyte-conditioned medium. SMC migration was inhibited by anti-MCP-1 and anti-CCR2 antibodies added to leukocyte-conditioned medium (<xref ref-type="fig" rid="pone-0004187-g002">Fig. 2</xref>).</p><fig id="pone-0004187-g002" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0004187.g002</object-id><label>Figure 2</label><caption><title>Migration of SMCs <italic>in vitro</italic>.</title><p>SMC migration was induced by leukocyte-conditioned medium and MCP-1 and inhibited by neutralizing antibodies against MCP-1 and CCR2. &#x0002a;p&#x0003c;0.05.</p></caption><graphic xlink:href="pone.0004187.g002"/></fig><p>To further examine the role of MCP-1 in SMC recruitment to allografts, we transplanted hearts from Balb mice into B56/c57-GFP mice. Recipients were treated with anti-MCP-1 antibodies or isotype control antibodies for 5 days, starting on day 5 after transplantation. At sacrifice on day 10, the number of host-derived SMCs and the grade of the inflammatory response in the graft were assessed by confocal microscopy. Macroscopically, the control hearts appeared to be more edematous. Microscopic analysis revealed that anti-MCP-1 treatment significantly decreased the number of CD45<sup>&#x0002b;</sup> and CD68<sup>&#x0002b;</sup> leukocytes (<xref ref-type="fig" rid="pone-0004187-g003">Fig. 3A&#x02013;E</xref>), suggesting a crucial role for MCP-1 in the inflammatory response. We did not observe a difference in CD3<sup>&#x0002b;</sup>, CD8<sup>&#x0002b;</sup>, or CD4<sup>&#x0002b;</sup> lymphocytes. Owing to the lower sensitivity of the CD3-specific antibodies, the number of CD3<sup>&#x0002b;</sup> cells was less than the sum of CD4<sup>&#x0002b;</sup> and CD8<sup>&#x0002b;</sup> cells. Host-derived cells were mostly present in small arterioles and were scarce in large arterioles (<xref ref-type="fig" rid="pone-0004187-g004">Fig. 4A, B</xref>). MCP-1 treatment also decreased the number of host-derived SMC in arterioles (1.58&#x000b1;0.53&#x00025; vs. 0.89&#x000b1;0.68&#x00025; in controls, p&#x0003c;0.05). Consistent with these findings, immunostaining for MCP-1 in human cardiac allografts showed that MCP-1 was expressed to a much greater extent around small arterioles and in areas with increased cellular inflammation (<xref ref-type="fig" rid="pone-0004187-g004">Fig. 4C</xref>). The results further imply that MCP-1 plays a pivotal role in the accumulation of host-derived SMCs in cardiac allografts.</p><fig id="pone-0004187-g003" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0004187.g003</object-id><label>Figure 3</label><caption><title>Immnunohistochemical analysis of mouse cardiac allograft treated anti-MCP-1 or isotypic control.</title><p>(A and B) Distribution of CD45<sup>&#x0002b;</sup> leukocytes in cardiac allografts treated with anti-MCP-1 antibodies (A) and control isotypic antibodies (B). (C and D) Distribution of CD68<sup>&#x0002b;</sup> leukocytes in cardiac allografts treated with antibodies against MCP-1 antibodies (C) and control isotypic antibodies (D). Blue, positive signal; red, nuclear counterstaining. (E) Numbers of &#x003b1;SMA-positive vessels and leukocytes expressing CD45, CD68, CD3, CD4, and CD8. &#x0002a;p&#x0003c;0.05.</p></caption><graphic xlink:href="pone.0004187.g003"/></fig><fig id="pone-0004187-g004" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0004187.g004</object-id><label>Figure 4</label><caption><title>Staining of mouse cardiac allografts for &#x003b1;SMA to identify the origin of cells expressing &#x003b1;SMA.</title><p>(A and B) Host-derived SMCs were present in arterioles with a single layer of SMCs (yellow) (A) but not in those with more SMC layers (B). Arrows indicate host-derived cells. Blue, &#x003b1;SMA; green, green fluorescent protein; red, nuclear counterstaining. Confocal microscopy analysis is followed by hematoxylin-eosin staining of parallel sections in order to present structure of vessels. Staining of human cardiac allografts for MCP-1 revealed MCP-1 around the small arterioles in an area with inflammation (C).</p></caption><graphic xlink:href="pone.0004187.g004"/></fig></sec></sec><sec id="s4"><title>Discussion</title><p>In this study, we analyzed the accumulation of host-derived &#x003b1;SMA-positive cells in arterioles in biopsies of human cardiac allografts. Regression analysis of the clinical data indicated that the number of host-derived SMCs in arterioles was associated with acute rejection and the number of infiltrated leukocytes in the allografts. In vitro, MCP-1 released from leukocytes was crucial for SMC migration. In mice that received allogenic heart transplants, MCP-1 was a major factor in SMC recruitment to transplanted vessels; mice treated with anti-MCP-1 antibodies had significantly fewer host-derived SMCs in their grafts. These observations suggest that inflammation and MCP-1 are pivotal in the recruitment of host-derived SMCs into transplanted organs.</p><p>During acute rejection episodes, transplanted grafts exhibit different grades of inflammation, which lead to apoptotic and necrotic tissue damage in parallel with the initiation of healing. During inflammation, leukocytes release proinflammatory cytokines (e.g., interleukins 1&#x003b1; and 6, tumor necrosis factor-&#x003b1;, MCP-1, stromal cell&#x02013;derived factor 1, and transforming growth factor &#x003b2;1) that contribute both to initiation of the inflammation and to healing <xref ref-type="bibr" rid="pone.0004187-Nian1">&#x0005b;13&#x0005d;</xref>. We found signs of acute inflammation and an increase in the number of host-derived SMC that parallel the grade of rejection. These findings suggest that inflammation is a factor in the recruitment of SMCs into transplanted grafts.</p><p>Acute rejection has been directly related to cardiac death and to transplant vasculopathy characterized by occlusive vascular narrowing due to accumulation and proliferation of SMCs in the vascular intima, leading to intimal hyperplasia <xref ref-type="bibr" rid="pone.0004187-Mitchell1">&#x0005b;14&#x0005d;</xref>. Previously, we showed that host-derived SMCs appear in the graft early after transplantation and start to accumulate within 1 month <xref ref-type="bibr" rid="pone.0004187-Religa1">&#x0005b;10&#x0005d;</xref>. Since the number of SMCs was not related to the time between transplantation and biopsy, we hypothesized that SMC recruitment is facilitated by other factors, such as immune-mediated damage of the heart after transplantation <xref ref-type="bibr" rid="pone.0004187-Minami1">&#x0005b;15&#x0005d;</xref>.</p><p>Indeed, the number of accumulated host-derived cells in the graft correlated strongly with the number of CD45<sup>&#x0002b;</sup> leukocytes and the grade of rejection, confirming that inflammation is strongly related to the recruitment of host-derived cells into the graft vessels. In support of this hypothesis, we previously found that an allogenic response in rats leads to apoptosis of transplanted SMCs that may affect the survival of host-derived cells that migrate to the transplanted vessels <xref ref-type="bibr" rid="pone.0004187-Religa1">&#x0005b;10&#x0005d;</xref>. We have also shown that an immunosuppression regimen can protect the allograft from damage and reduce the recruitment of host-derived cells <xref ref-type="bibr" rid="pone.0004187-Davies1">&#x0005b;16&#x0005d;</xref>. Transplant recipients with lower rejection grades or no acute rejection episodes have a lower risk of late chronic rejection and in particular transplant vascular sclerosis <xref ref-type="bibr" rid="pone.0004187-Stoica1">&#x0005b;17&#x0005d;</xref>. Thus, inflammation may be an underestimated cause for increased recruitment of progenitor cells to injured tissue to initiate vascular repair.</p><p>In studies to identify the inflammatory factors involved in the migration of SMCs in vitro, we found that SMCs migrated in response to leukocyte-conditioned medium and that MCP-1 and its receptor CCR2 were major factors in that migration. In vivo, MCP-1 and CCR2 played a pivotal role in recruiting SMCs into heterotopic heart grafts in mice. These observations support a crucial role for MCP-1 and CCR2 in the recruitment of vascular progenitor cells, perhaps to assist in healing. Indeed, MCP-1 is thought to contribute to healing of vascular injury <xref ref-type="bibr" rid="pone.0004187-Morimoto1">&#x0005b;18&#x0005d;</xref> by recruiting vascular progenitor cells <xref ref-type="bibr" rid="pone.0004187-Fujiyama1">&#x0005b;19&#x0005d;</xref>. In atherosclerosis, MCP-1 is involved in recruitment of monocytes/macrophages into the vascular wall and in the formation of lipid cores and atherosclerotic plaques <xref ref-type="bibr" rid="pone.0004187-Cheng1">&#x0005b;20&#x0005d;</xref>.</p><p>Other nonspecific risk factors for transplant vasculopathy, including smoking, hypertension, and coronary artery disease, did not correlate significantly with the number of host-derived SMCs in the vascular wall, perhaps because of the small numbers of patients with those risk factors. Reduction of circulating endothelial progenitor cells in the blood seems to be related to the level of vascular damage <xref ref-type="bibr" rid="pone.0004187-Fadini1">&#x0005b;21&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0004187-Vasa2">&#x0005b;24&#x0005d;</xref>. Moreover, factors such as hypertension and diabetes appear to impair the migration of endothelial progenitor cells <xref ref-type="bibr" rid="pone.0004187-Vasa2">&#x0005b;24&#x0005d;</xref>. Vascular progenitor cells appear to be specifically recruited into injured tissues, but the factors leading to their recruitment and their functions in the healing of tissue damage are poorly understood <xref ref-type="bibr" rid="pone.0004187-Loomans1">&#x0005b;25&#x0005d;</xref>, <xref ref-type="bibr" rid="pone.0004187-Wojakowski1">&#x0005b;26&#x0005d;</xref>. The physiological status of arteries in these diseases affects the number of circulating progenitors by influencing their maturation, release from the bone marrow, and accumulation in injured tissues <xref ref-type="bibr" rid="pone.0004187-Leri1">&#x0005b;27&#x0005d;</xref>&#x02013;<xref ref-type="bibr" rid="pone.0004187-Soler1">&#x0005b;29&#x0005d;</xref>. Thus, inflammation may lead to the recruitment of these cells. However, our findings do not indicate the source of host-derived SMCs and vascular progenitors.</p><p>In summary, we provide evidence that inflammation and MCP-1 are pivotal in the recruitment of host-derived SMCs into transplanted hearts. This knowledge may be useful in designing protocols aimed at reducing the number of host-derived SMC in cardiac allografts and increasing the number of progenitor cells to limit tissue damage and facilitate healing at sites of tissue injury.</p></sec></body><back><ref-list><title>References</title><ref id="pone.0004187-Libby1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Libby</surname><given-names>P</given-names></name><name><surname>Pober</surname><given-names>JS</given-names></name></person-group><year>2001</year><article-title>Chronic rejection.</article-title><source>Immunity</source><volume>14</volume><fpage>387</fpage><lpage>397</lpage><pub-id pub-id-type="pmid">11336684</pub-id></citation></ref><ref id="pone.0004187-Lietz1"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lietz</surname><given-names>K</given-names></name><name><surname>Miller</surname><given-names>LW</given-names></name></person-group><year>2004</year><article-title>Current understanding and management of allograft vasculopathy.</article-title><source>Semin Thorac Cardiovasc Surg</source><volume>16</volume><fpage>386</fpage><lpage>394</lpage><pub-id pub-id-type="pmid">15635545</pub-id></citation></ref><ref id="pone.0004187-Bojakowski1"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bojakowski</surname><given-names>K</given-names></name><name><surname>Religa</surname><given-names>P</given-names></name><name><surname>Bojakowska</surname><given-names>M</given-names></name><name><surname>Hedin</surname><given-names>U</given-names></name><name><surname>Gaciong</surname><given-names>Z</given-names></name><etal/></person-group><year>2000</year><article-title>Arteriosclerosis in rat aortic allografts: early changes in endothelial integrity and smooth muscle phenotype.</article-title><source>Transplantation</source><volume>70</volume><fpage>65</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">10919577</pub-id></citation></ref><ref id="pone.0004187-Hillebrands1"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hillebrands</surname><given-names>JL</given-names></name><name><surname>Klatter</surname><given-names>FA</given-names></name><name><surname>van den Hurk</surname><given-names>BM</given-names></name><name><surname>Popa</surname><given-names>ER</given-names></name><name><surname>Nieuwenhuis</surname><given-names>P</given-names></name><etal/></person-group><year>2001</year><article-title>Origin of neointimal endothelium and alpha-actin-positive smooth muscle cells in transplant arteriosclerosis.</article-title><source>J Clin Invest</source><volume>107</volume><fpage>1411</fpage><lpage>1422</lpage><pub-id pub-id-type="pmid">11390423</pub-id></citation></ref><ref id="pone.0004187-Hu1"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Torsney</surname><given-names>E</given-names></name><name><surname>Afzal</surname><given-names>AR</given-names></name><name><surname>Davison</surname><given-names>F</given-names></name><etal/></person-group><year>2004</year><article-title>Abundant progenitor cells in the adventitia contribute to atherosclerosis of vein grafts in ApoE-deficient mice.</article-title><source>J Clin Invest</source><volume>113</volume><fpage>1258</fpage><lpage>1265</lpage><pub-id pub-id-type="pmid">15124016</pub-id></citation></ref><ref id="pone.0004187-Sata1"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sata</surname><given-names>M</given-names></name><name><surname>Saiura</surname><given-names>A</given-names></name><name><surname>Kunisato</surname><given-names>A</given-names></name><name><surname>Tojo</surname><given-names>A</given-names></name><name><surname>Okada</surname><given-names>S</given-names></name><etal/></person-group><year>2002</year><article-title>Hematopoietic stem cells differentiate into vascular cells that participate in the pathogenesis of atherosclerosis.</article-title><source>Nat Med</source><volume>8</volume><fpage>403</fpage><lpage>409</lpage><pub-id pub-id-type="pmid">11927948</pub-id></citation></ref><ref id="pone.0004187-Orloff1"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Orloff</surname><given-names>SL</given-names></name><name><surname>Streblow</surname><given-names>DN</given-names></name><name><surname>Soderberg-Naucler</surname><given-names>C</given-names></name><name><surname>Yin</surname><given-names>Q</given-names></name><name><surname>Kreklywich</surname><given-names>C</given-names></name><etal/></person-group><year>2002</year><article-title>Elimination of donor-specific alloreactivity prevents cytomegalovirus-accelerated chronic rejection in rat small bowel and heart transplants.</article-title><source>Transplantation</source><volume>73</volume><fpage>679</fpage><lpage>688</lpage><pub-id pub-id-type="pmid">11907411</pub-id></citation></ref><ref id="pone.0004187-SoderbergNaucler1"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Soderberg-Naucler</surname><given-names>C</given-names></name><name><surname>Emery</surname><given-names>VC</given-names></name></person-group><year>2001</year><article-title>Viral infections and their impact on chronic renal allograft dysfunction.</article-title><source>Transplantation</source><volume>71</volume><fpage>SS24</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">11583485</pub-id></citation></ref><ref id="pone.0004187-Stewart1"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stewart</surname><given-names>S</given-names></name><name><surname>Winters</surname><given-names>GL</given-names></name><name><surname>Fishbein</surname><given-names>MC</given-names></name><name><surname>Tazelaar</surname><given-names>HD</given-names></name><name><surname>Kobashigawa</surname><given-names>J</given-names></name><etal/></person-group><year>2005</year><article-title>Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection.</article-title><source>J Heart Lung Transplant</source><volume>24</volume><fpage>1710</fpage><lpage>1720</lpage><pub-id pub-id-type="pmid">16297770</pub-id></citation></ref><ref id="pone.0004187-Religa1"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Religa</surname><given-names>P</given-names></name><name><surname>Bojakowski</surname><given-names>K</given-names></name><name><surname>Bojakowska</surname><given-names>M</given-names></name><name><surname>Gaciong</surname><given-names>Z</given-names></name><name><surname>Thyberg</surname><given-names>J</given-names></name><etal/></person-group><year>2005</year><article-title>Allogenic immune response promotes the accumulation of host-derived smooth muscle cells in transplant arteriosclerosis.</article-title><source>Cardiovasc Res</source><volume>65</volume><fpage>535</fpage><lpage>545</lpage><pub-id pub-id-type="pmid">15639493</pub-id></citation></ref><ref id="pone.0004187-Lo1"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lo</surname><given-names>YM</given-names></name><name><surname>Tein</surname><given-names>MS</given-names></name><name><surname>Lau</surname><given-names>TK</given-names></name><name><surname>Haines</surname><given-names>CJ</given-names></name><name><surname>Leung</surname><given-names>TN</given-names></name><etal/></person-group><year>1998</year><article-title>Quantitative analysis of fetal DNA in maternal plasma and serum: implications for noninvasive prenatal diagnosis.</article-title><source>Am J Hum Genet</source><volume>62</volume><fpage>768</fpage><lpage>775</lpage><pub-id pub-id-type="pmid">9529358</pub-id></citation></ref><ref id="pone.0004187-Huang1"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>BJ</given-names></name><name><surname>Yin</surname><given-names>H</given-names></name><name><surname>Huang</surname><given-names>YF</given-names></name><name><surname>Xu</surname><given-names>JF</given-names></name><name><surname>Xiong</surname><given-names>P</given-names></name><etal/></person-group><year>2006</year><article-title>Gene therapy using adenoviral vector encoding 4-1BBIg gene significantly prolonged murine cardiac allograft survival.</article-title><source>Transpl Immunol</source><volume>16</volume><fpage>88</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">16860710</pub-id></citation></ref><ref id="pone.0004187-Nian1"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nian</surname><given-names>M</given-names></name><name><surname>Lee</surname><given-names>P</given-names></name><name><surname>Khaper</surname><given-names>N</given-names></name><name><surname>Liu</surname><given-names>P</given-names></name></person-group><year>2004</year><article-title>Inflammatory cytokines and postmyocardial infarction remodeling.</article-title><source>Circ Res</source><volume>94</volume><fpage>1543</fpage><lpage>1553</lpage><pub-id pub-id-type="pmid">15217919</pub-id></citation></ref><ref id="pone.0004187-Mitchell1"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mitchell</surname><given-names>RN</given-names></name><name><surname>Libby</surname><given-names>P</given-names></name></person-group><year>2007</year><article-title>Vascular remodeling in transplant vasculopathy.</article-title><source>Circ Res</source><volume>100</volume><fpage>967</fpage><lpage>978</lpage><pub-id pub-id-type="pmid">17431198</pub-id></citation></ref><ref id="pone.0004187-Minami1"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Minami</surname><given-names>E</given-names></name><name><surname>Laflamme</surname><given-names>MA</given-names></name><name><surname>Saffitz</surname><given-names>JE</given-names></name><name><surname>Murry</surname><given-names>CE</given-names></name></person-group><year>2005</year><article-title>Extracardiac progenitor cells repopulate most major cell types in the transplanted human heart.</article-title><source>Circulation</source><volume>112</volume><fpage>2951</fpage><lpage>2958</lpage><pub-id pub-id-type="pmid">16275883</pub-id></citation></ref><ref id="pone.0004187-Davies1"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Davies</surname><given-names>WR</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Oi</surname><given-names>K</given-names></name><name><surname>Bailey</surname><given-names>KR</given-names></name><name><surname>Tazelaar</surname><given-names>HD</given-names></name><etal/></person-group><year>2005</year><article-title>Cyclosporine decreases vascular progenitor cell numbers after cardiac transplantation and attenuates progenitor cell growth in vitro.</article-title><source>J Heart Lung Transplant</source><volume>24</volume><fpage>1868</fpage><lpage>1877</lpage><pub-id pub-id-type="pmid">16297794</pub-id></citation></ref><ref id="pone.0004187-Stoica1"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stoica</surname><given-names>SC</given-names></name><name><surname>Cafferty</surname><given-names>F</given-names></name><name><surname>Pauriah</surname><given-names>M</given-names></name><name><surname>Taylor</surname><given-names>CJ</given-names></name><name><surname>Sharples</surname><given-names>LD</given-names></name><etal/></person-group><year>2006</year><article-title>The cumulative effect of acute rejection on development of cardiac allograft vasculopathy.</article-title><source>J Heart Lung Transplant</source><volume>25</volume><fpage>420</fpage><lpage>425</lpage><pub-id pub-id-type="pmid">16563972</pub-id></citation></ref><ref id="pone.0004187-Morimoto1"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Morimoto</surname><given-names>H</given-names></name><name><surname>Takahashi</surname><given-names>M</given-names></name><name><surname>Izawa</surname><given-names>A</given-names></name><name><surname>Ise</surname><given-names>H</given-names></name><name><surname>Hongo</surname><given-names>M</given-names></name><etal/></person-group><year>2006</year><article-title>Cardiac overexpression of monocyte chemoattractant protein-1 in transgenic mice prevents cardiac dysfunction and remodeling after myocardial infarction.</article-title><source>Circ Res</source><volume>99</volume><fpage>891</fpage><lpage>899</lpage><pub-id pub-id-type="pmid">16990567</pub-id></citation></ref><ref id="pone.0004187-Fujiyama1"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fujiyama</surname><given-names>S</given-names></name><name><surname>Amano</surname><given-names>K</given-names></name><name><surname>Uehira</surname><given-names>K</given-names></name><name><surname>Yoshida</surname><given-names>M</given-names></name><name><surname>Nishiwaki</surname><given-names>Y</given-names></name><etal/></person-group><year>2003</year><article-title>Bone marrow monocyte lineage cells adhere on injured endothelium in a monocyte chemoattractant protein-1-dependent manner and accelerate reendothelialization as endothelial progenitor cells.</article-title><source>Circ Res</source><volume>93</volume><fpage>980</fpage><lpage>989</lpage><pub-id pub-id-type="pmid">14525810</pub-id></citation></ref><ref id="pone.0004187-Cheng1"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>C</given-names></name><name><surname>Tempel</surname><given-names>D</given-names></name><name><surname>van Haperen</surname><given-names>R</given-names></name><name><surname>de Boer</surname><given-names>HC</given-names></name><name><surname>Segers</surname><given-names>D</given-names></name><etal/></person-group><year>2007</year><article-title>Shear stress-induced changes in atherosclerotic plaque composition are modulated by chemokines.</article-title><source>J Clin Invest</source><volume>117</volume><fpage>616</fpage><lpage>626</lpage><pub-id pub-id-type="pmid">17304353</pub-id></citation></ref><ref id="pone.0004187-Fadini1"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fadini</surname><given-names>GP</given-names></name><name><surname>Miorin</surname><given-names>M</given-names></name><name><surname>Facco</surname><given-names>M</given-names></name><name><surname>Bonamico</surname><given-names>S</given-names></name><name><surname>Baesso</surname><given-names>I</given-names></name><etal/></person-group><year>2005</year><article-title>Circulating endothelial progenitor cells are reduced in peripheral vascular complications of type 2 diabetes mellitus.</article-title><source>J Am Coll Cardiol</source><volume>45</volume><fpage>1449</fpage><lpage>1457</lpage><pub-id pub-id-type="pmid">15862417</pub-id></citation></ref><ref id="pone.0004187-Tepper1"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tepper</surname><given-names>OM</given-names></name><name><surname>Galiano</surname><given-names>RD</given-names></name><name><surname>Capla</surname><given-names>JM</given-names></name><name><surname>Kalka</surname><given-names>C</given-names></name><name><surname>Gagne</surname><given-names>PJ</given-names></name><etal/></person-group><year>2002</year><article-title>Human endothelial progenitor cells from type II diabetics exhibit impaired proliferation, adhesion, and incorporation into vascular structures.</article-title><source>Circulation</source><volume>106</volume><fpage>2781</fpage><lpage>2786</lpage><pub-id pub-id-type="pmid">12451003</pub-id></citation></ref><ref id="pone.0004187-Vasa1"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vasa</surname><given-names>M</given-names></name><name><surname>Fichtlscherer</surname><given-names>S</given-names></name><name><surname>Adler</surname><given-names>K</given-names></name><name><surname>Aicher</surname><given-names>A</given-names></name><name><surname>Martin</surname><given-names>H</given-names></name><etal/></person-group><year>2001</year><article-title>Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease.</article-title><source>Circulation</source><volume>103</volume><fpage>2885</fpage><lpage>2890</lpage><pub-id pub-id-type="pmid">11413075</pub-id></citation></ref><ref id="pone.0004187-Vasa2"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vasa</surname><given-names>M</given-names></name><name><surname>Fichtlscherer</surname><given-names>S</given-names></name><name><surname>Aicher</surname><given-names>A</given-names></name><name><surname>Adler</surname><given-names>K</given-names></name><name><surname>Urbich</surname><given-names>C</given-names></name><etal/></person-group><year>2001</year><article-title>Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease.</article-title><source>Circ Res</source><volume>89</volume><fpage>E1</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">11440984</pub-id></citation></ref><ref id="pone.0004187-Loomans1"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Loomans</surname><given-names>CJ</given-names></name><name><surname>de Koning</surname><given-names>EJ</given-names></name><name><surname>Staal</surname><given-names>FJ</given-names></name><name><surname>Rookmaaker</surname><given-names>MB</given-names></name><name><surname>Verseyden</surname><given-names>C</given-names></name><etal/></person-group><year>2004</year><article-title>Endothelial progenitor cell dysfunction: a novel concept in the pathogenesis of vascular complications of type 1 diabetes.</article-title><source>Diabetes</source><volume>53</volume><fpage>195</fpage><lpage>199</lpage><pub-id pub-id-type="pmid">14693715</pub-id></citation></ref><ref id="pone.0004187-Wojakowski1"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wojakowski</surname><given-names>W</given-names></name><name><surname>Tendera</surname><given-names>M</given-names></name><name><surname>Michalowska</surname><given-names>A</given-names></name><name><surname>Majka</surname><given-names>M</given-names></name><name><surname>Kucia</surname><given-names>M</given-names></name><etal/></person-group><year>2004</year><article-title>Mobilization of CD34/CXCR4&#x0002b;, CD34/CD117&#x0002b;, c-met&#x0002b; stem cells, and mononuclear cells expressing early cardiac, muscle, and endothelial markers into peripheral blood in patients with acute myocardial infarction.</article-title><source>Circulation</source><volume>110</volume><fpage>3213</fpage><lpage>3220</lpage><pub-id pub-id-type="pmid">15533859</pub-id></citation></ref><ref id="pone.0004187-Leri1"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Leri</surname><given-names>A</given-names></name><name><surname>Kajstura</surname><given-names>J</given-names></name><name><surname>Anversa</surname><given-names>P</given-names></name></person-group><year>2005</year><article-title>Cardiac stem cells and mechanisms of myocardial regeneration.</article-title><source>Physiol Rev</source><volume>85</volume><fpage>1373</fpage><lpage>1416</lpage><pub-id pub-id-type="pmid">16183916</pub-id></citation></ref><ref id="pone.0004187-Werner1"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Werner</surname><given-names>N</given-names></name><name><surname>Kosiol</surname><given-names>S</given-names></name><name><surname>Schiegl</surname><given-names>T</given-names></name><name><surname>Ahlers</surname><given-names>P</given-names></name><name><surname>Walenta</surname><given-names>K</given-names></name><etal/></person-group><year>2005</year><article-title>Circulating endothelial progenitor cells and cardiovascular outcomes.</article-title><source>N Engl J Med</source><volume>353</volume><fpage>999</fpage><lpage>1007</lpage><pub-id pub-id-type="pmid">16148285</pub-id></citation></ref><ref id="pone.0004187-Soler1"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Soler</surname><given-names>MJ</given-names></name><name><surname>Martinez-Estrada</surname><given-names>OM</given-names></name><name><surname>Puig-Mari</surname><given-names>JM</given-names></name><name><surname>Marco-Feliu</surname><given-names>D</given-names></name><name><surname>Oliveras</surname><given-names>A</given-names></name><etal/></person-group><year>2005</year><article-title>Circulating endothelial progenitor cells after kidney transplantation.</article-title><source>Am J Transplant</source><volume>5</volume><fpage>2154</fpage><lpage>2159</lpage><pub-id pub-id-type="pmid">16095494</pub-id></citation></ref></ref-list><fn-group><fn fn-type="conflict"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="financial-disclosure"><p><bold>Funding: </bold>This work was supported by grants from the Science Research Committee MNiSW 3B138, Swedish Research Council (K2004-16X-12615-07A, K2007-56X-12615-10-3), the Swedish Society of Medicine (2003-633), the Tobias Foundation (28/03 and 29/04), and the Heart and Lung Foundation (199941305, 200241138, 20030055, and 20050266). King Gustaf V's 80-Year Anniversary Foundation, Swedish Cancer Foundation (060253), and Children's Cancer Foundation (05/100). C.S.-N. is a Royal Swedish Academy of Science Research Fellow supported by a grant from the Knut and Alice Wallenberg Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</p></fn></fn-group></back></article> 